Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России
Список исп. литературыСкрыть список 1. Алфимов П.В., Мосолов С.Н. Роль дофаминовых Д3-рецепторов в механизме действия современных антипсихотиков. Современная терапия психических расстройств. 2014; 1: 2–9. 2. Быков Ю.В., Беккер Р.А., Морозов П.В. Эффективность карипразина в лечении шизофрении, особенно с преобладанием негативной симптоматики. Психиатр. и психофармакотер. 2018; 5: 27–37. 3. Горобец Л.Н., Литвинов A.В. Карипразин: нейроэндокринные и метаболические аспекты переносимости. Ж. современная терапия психических расстройств. 2020; 3: 19–27. 4. Дьяков И.Н., Зырянов С.К. Клинико-экономическая эффективность применения карипразина при шизофрении. Ж. невр. психиатр им С.С. Корсакова. 2019; 119 (7): 69–77. 5. Иванов С.В., Смулевич А.Б., Воронова Е.И. Антипсихотик нового поколения карипразин (Реагила) в лечении шизофрении: спектр клинической эффективности и безопасности. Психиатрия. 2020; 18 (4): 139–48. 6. Медведев В.Э. Карипразин – новый антипсихотик для лечения шизофрении.. Современная терапия психических расстройствю. 2019; 2: 22–9. 7. Мосолов С.Н., Ялтонская П.А. Алгоритм терапии первичной негативной симптоматики при шизофрении. Совр. тер. психич. расстр. 2020; 2: 2–10. 8. Сэдок Б.Д., Сассмэн Н., Сэдок В.Э. Руководство Коплана и Сэдока по медикаментозному лечению в психиатрии. Перевод с англ. под общ. редакц. проф. А.С. Аведисовой. -М.МЕДпресс.-информ. 2021; 476 c. 9. Шайдеггер Ю.М., Доровских И.В. Возможности применения при аддитивной патологии парциальных агонистов D3-рецепторов. Эффективная фармакотерапия. 2020; 16 (4): 30–4. 10. Шмуклер А.Б. Карипразин – антипсихотик с новыми универсальными потенциальными возможностями для лечения шизофрении и аффективных расстройств. Cоц. клин. психиатр. 2014; 24 (2): 72–4. 11. Altinbas K., Guloksuz S., Oral E.T. Clinical potential of cariprazine in the treatment of acute mania. Psychitr. Danub. 2013; 5(3): 207–13. 12. Caccia S., Invernizzi R.W., Nobili A., Pasina L. A new generation of antipsychotics; pharmacology and clinical utility of cariprazine in schizophrenia. Therapeutics and clinical ristmanagement. 2013; 9: 319–28. 13. Citrome L. Cariprazine for the treatment of schizophrenia: A Review of this Dopamine D3-Preferring D1/D2 Receptor Partial Agonist.. Clin. Schizophr. Relat. Psychoses. 2016; 10 (2): 109–19. 14. Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G; Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies. Neuropsych Dis Treat. 2021; 17: 957–70. 15. Citrome L., Durgam S., Lu K., Ferguson P., Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J. Clin. Psychiatry. 2016; 77 (1): 109–15. 16. Corponi F., Seretti A., Montgomery S., Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta- regression of randomized-controlled trials. Jnt. Clin. Psychopharmocol.- 2017; 32 (6): 309–18. 17. Correll C.U., Jain R., Meyer J.M., Perjclou A., Carrothers T., Barabassy A., Patel M., Earley W. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr. Dis Treat.-2019; 15: 2537–50. 18. Cutler A.J., Durgam S., Wang Y. et al. Evaluation of the long-term safety and tolerability of cariprazinein patients with schizophrenia results from a 1-year open-label study. CNS Spectr. 2018; 23 (1): 39–50. 19. Durgam S., Cunter A.J., Li K. et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo and active-controlled trial. Clin. Psychiatry; 2015; 76: 1574–82. 20. Durgam S., Earley W., Li K. еt al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr. Res.2016; 176 (2-3): 264–71. 21. Earley W., Burges M.V., Rekeda L. et al. Cariprazine Treatment of bipolar depression a randomized double-blind placebo- controlled phase 3 study. Am.J. Psychhatiy.- 2019; 178 (6): 439–48. 22. Earley W., Durgam S., Li K., Laszlovsky I., Debelle M., Kane J.M. Safety and tolerability of cariprazinein patients with acute exacerbation of schizophrenia a pooled analysis of four phase II-III randomized, double-blind, placebo-controlled studies. Jnt. Clin. Psychopharmacol. 2017; 32 (6): 319–28. 23. Fleischhacker W., Galderisi S., Laszlovszki I., Szatmari B., Barabassy A., Acsai K., Szalai E., Harsany J., EarleyW., Patel M., Nemeth G. The efficacy of cariprazinein negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur. Psychiatry. 2019; 58: 1–9. 24. Grunder G. Cariprazine, an orally active D2/D3-receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Current Opinion in Inestigational Drugs. 2010; 10 (7): 823–32. 25. Jucker G., de Bartolomers A., Gorwood Ph., Mosolov S., Pani L., Rossy A., Sanjuan J. Towards a framework for Treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment. 2014; 10: 1867–78. https:. doi.org/10.2147/ndt.s61672 26. Kane J.M., Zukin S., Wang Y. et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia results from an International, phase III clinical trial. J. Clin. Psychopharmacol. 2015; 35 (4): 367–73. 27. Kapas M., Meszaros G.P., Yu B. et al. (P3.c051) Comparison of the pharmacokinetic behavior of RGH-188 in schizophrenic patients and bealthyvohunteirs.Eur.Neuropsychopharmacol. 2008; 18 (suppl. 4): S.433. 28. Keck P.E. Jr., Zukun S., Lu K. Cariprazine effects on YMRS items: results of a pooled analysis of 3 randomized, double-blind, placebo-controlled trials in bipolar manis. 26th ECNP Congress, 5–9 Oct. 2013, Barselona, Spain. Eur. Neuropsychopharm. 2013; 23 (2): 375–76. 29. Kraus M., Zhu Y., Huhn M., Schneider- Thoma J., Bighelti I, Nico- lakopoulou A., Leucht S. Antipsychotic drugs for patients with schizophrenia and predominant or prominent nrgative symptoms; a systematic review and meta-analysis . Eur. Arch psychiatry Clin. Neurosci. 2018; 268 (7): 625–39. 30. Mosolov S.N., Potapov A.V., Ushakov U.V., Shafarenko A.A., Kostykova E.B. Designand validation of standardized clinical and functional remission criteria in schizophrenia . Neuropsychiatric Disease and Treatment. 2014; 10: 167–81. 31. Nemeth G., Laszlovszki I., Czobor P.,Szalai E., Szatmary B., Harsanyi J., Barabassy A., Debelle M., Durgam S., Bitter I., Marder S., Fleischhacker W.W.Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomized, double-blind, controlled trial. Lancet.-2017; 389 (10074): 1103–13. https:. doi.org/10.1016/S0140-6736(17)30060-0 32. Roberts R.S., Findlay L.J., El-Mallakb R.S. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr. Dis. Treat. 2016; 12: 1837–42. 33. Scarff J.R. Cariprazine for schizophrenia and bipolar disorder. Innov. Clin. Neurosci. 2016; 13 (9–10): 49–52. 34. Stahl S. Essential Psychopharmacology Neuroscientific Basis and Practical. Application. 4rd. ed Cambridge: Cambridge University Press. 2013. 35. Stahl S.M. Case Studies: Stahls Essential Psychopharmacology: Volume 2, Cambridge University Press. I-st Ed. 2017. 36. Werner F.M., Covenas R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine . Ther. Chin. Risk. Manag. 2015; 11: 1657–61. 37. Zhao M.J., Oin B., Wang J.B., Zhang Y.P., Zhao J.T., Mao Y.G., Zhang X.Y., Zhang R.L. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of schizophrenia: Meta-analysis of Randomized Placebo-Controlled Trials. J. Clin. Psychoparmacol. 2018; 38 (1): 55–59.